Should Employers Cover GLP-1 Weight-Loss Drugs in 2027?
For employers, GLP-1 medications have evolved from a pharmacy issue into a major benefits strategy decision.
Drugs in this category can provide meaningful clinical benefits for appropriate patients. But rapidly growing utilization and cost are forcing employers to determine how—or whether—they can sustainably cover GLP-1 medications for weight management.
The pressure is significant.
Pharmacy now represents approximately 25% of total healthcare spending among employers surveyed by Business Group on Health, and employers expect drug costs to increase another 12% in 2027 before interventions.[1]
At the same time, employer coverage of GLP-1 medications for obesity is moving in the opposite direction. Coverage among employers surveyed by Business Group on Health declined from 72% in 2025 to 60% in 2026.[1]
So should employers cover GLP-1 medications in 2027?
There isn't a universal answer. Employers should evaluate GLP-1 coverage as part of their broader pharmacy and healthcare strategy—not simply as a yes-or-no formulary decision.
For employers with 50, 100, 250 or 500+ employees, that means understanding the potential clinical value, actual utilization, pharmacy contract, eligibility criteria and financial exposure before deciding what belongs in the health plan.
Why Are Employers Reconsidering GLP-1 Coverage?
GLP-1 medications were originally developed to help manage Type 2 diabetes, but indications have expanded.
Certain GLP-1 medications are now approved for weight management, and the FDA has also approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in certain adults with cardiovascular disease and obesity or overweight.[2]
That creates a legitimate benefits challenge.
Employers are not simply deciding whether to pay for a weight-loss drug.
They are evaluating medications that may have meaningful health benefits while simultaneously facing one of the most difficult healthcare cost environments in years.
Business Group on Health reports that nearly eight in ten employers in its GLP-1 survey said these medications were increasing their healthcare costs.[3]
Meanwhile, Mercer now projects total employer health-benefit cost per employee will rise 8.2% in 2027 even after planned cost-reduction measures—the largest increase since 2003.[4]
That puts GLP-1 coverage directly in the middle of the employer's affordability equation.
The Wrong Question: "Do We Cover GLP-1s?"
Employers often frame the decision too narrowly:
Do we cover weight-loss drugs, or don't we?
A better question is:
Under what circumstances can we provide clinically appropriate GLP-1 coverage while managing the financial impact on the health plan?
Between unrestricted coverage and complete exclusion are multiple strategies employers can evaluate.
Those can include eligibility requirements, prior authorization, clinical oversight, weight-management programs, formulary decisions and ongoing measurement of utilization and outcomes.
The goal should be to determine what makes sense for the employer's workforce rather than copying another company's benefits program.
7 Questions Employers Should Ask Before Making a GLP-1 Coverage Decision
1. What Are We Actually Spending on GLP-1 Medications?
Start with data.
Employers should determine how much the plan currently spends on GLP-1 medications, how quickly utilization is increasing and what portion of pharmacy spend they represent.
For a fully insured employer, the available information may be limited.
Level-funded and self-funded employers may have greater access to claims and pharmacy information, depending on their contracts and vendors.
Either way, leadership should attempt to establish a baseline before making a coverage decision.
A decision based only on the theoretical cost of the medication is less useful than one based on the actual experience of the workforce.
2. Why Are Employees Using Them?
Not every GLP-1 prescription represents the same clinical situation.
The employer and its advisors should distinguish between coverage for diabetes, obesity and other applicable FDA-approved indications rather than discussing every GLP-1 prescription as though it were identical.
This distinction is particularly important when evaluating exclusions or utilization-management programs.
The objective should be thoughtful plan design—not interfering with individual medical decisions between patients and their healthcare providers.
3. What Eligibility Requirements Are Appropriate?
Employers that offer GLP-1 obesity coverage increasingly attach conditions to it.
Business Group on Health previously reported that among employers covering GLP-1 medications for obesity, 90% required prior authorization, 54% required participation in a weight-management program and 48% required a particular BMI threshold and/or additional comorbidities beyond the FDA indication.[5]
Those approaches illustrate how employers are moving away from a simple covered/not-covered decision.
An employer might instead ask:
Is prior authorization appropriate?
Should coverage follow specific clinical criteria?
Should employees participate in a broader obesity-management program?
Which providers can prescribe through the plan?
How frequently should continued eligibility be reviewed?
Any such requirements should be developed with qualified clinical, legal and benefits advisors.
4. What Is Our PBM Actually Doing?
A GLP-1 strategy should also prompt a broader pharmacy question:
How well does the employer understand its PBM arrangement?
Employers should understand how their pharmacy benefit manager is compensated, how rebates are handled, how the formulary is constructed and what utilization-management programs are available.
This is becoming a much larger issue than GLP-1s alone.
Mercer reported in June that 41% of large employers are evaluating different contracting models offered by major PBMs, while 37% are evaluating new or emerging PBMs.[6]
A company experiencing rapid pharmacy inflation should therefore evaluate the underlying pharmacy arrangement—not merely one expensive drug category.
5. Are We Measuring Outcomes—or Only Cost?
This is one of the hardest parts of the equation.
More than half of employers covering GLP-1s for weight management in a Business Group on Health survey expected significant clinical benefits. However, the organization reported that relatively few had yet observed evidence of those benefits within their aggregated claims, such as lower obesity prevalence or reduced need for bariatric surgery.[3]
That doesn't prove the medications lack value.
It illustrates the time-horizon problem facing employers.
The expense appears immediately on the pharmacy claim.
Some potential health benefits may emerge much later.
That creates an especially difficult calculation for employers trying to balance annual budgets against long-term workforce health.
Employers offering coverage should determine in advance what they intend to measure.
6. What Happens If We Don't Cover Them?
Excluding GLP-1 medications also has consequences.
Employees may value access to obesity treatment. Coverage decisions can affect employee satisfaction and the perceived quality of the benefits package.
Employers competing for talent should therefore consider the employee side of the equation alongside the financial one.
A company does not need to offer every possible benefit.
But leadership should understand what employees value before eliminating a benefit solely because it is expensive.
The right decision for a 75-person construction company may differ substantially from the right decision for a 400-person professional-services firm.
Workforce demographics, recruiting environment, compensation strategy and employee expectations matter.
7. Is GLP-1 Coverage Part of a Larger Health Strategy?
This may be the most important question.
GLP-1 medications should not exist in isolation from the rest of the benefits program.
Employers should consider how coverage interacts with:
Diabetes management
Cardiovascular health
Obesity management
Primary care
Nutrition support
Behavioral health
Musculoskeletal health
Employee engagement
Preventive care
A sophisticated strategy asks whether the company is simply paying pharmacy claims or actually creating a coordinated approach to employee health.
Cover, Restrict or Exclude? Three Approaches Employers Can Evaluate
There are broadly three directions an employer might consider.
Option 1: Broad Coverage
The employer provides GLP-1 coverage according to the plan's standard pharmacy rules.
This maximizes access but may expose the plan to greater utilization and financial volatility.
Option 2: Coverage With Clinical and Utilization Requirements
The employer maintains coverage while implementing appropriate controls such as prior authorization, clinical eligibility requirements or participation in a coordinated weight-management program.
For many employers, this middle ground may warrant serious evaluation because it attempts to balance access with financial sustainability.
Option 3: Exclude Certain GLP-1 Coverage
Some employers may determine that coverage for weight management is currently unsustainable.
Business Group on Health's newest data suggests more employers are moving in this direction: obesity-related GLP-1 coverage declined from 72% in 2025 to 60% in 2026.[1]
An exclusion, however, should be considered in the context of the overall benefits strategy, applicable laws, plan documents, employee communications and the clinical conditions for which specific medications are prescribed.
Why This Matters Even More for Self-Funded Employers
For a fully insured employer, rising pharmacy utilization ultimately becomes part of the carrier's renewal calculation.
For a self-funded employer, pharmacy claims have a much more direct relationship to plan spending.
That makes visibility particularly valuable.
A self-funded employer should be asking:
What are we buying? What are we paying? Who is being paid along the way? And what results are we getting?
GLP-1s are one highly visible example of a much broader issue.
As expensive specialty medications, cancer therapies, cell and gene therapies and other advanced treatments become more common, pharmacy strategy will increasingly become part of the employer's overall healthcare financing strategy.
Don't Solve a Pharmacy Problem by Automatically Shifting Costs to Employees
Employers facing rising healthcare expenses frequently have the same lever available:
Increase employee cost-sharing.
That can lower the employer's immediate expense.
It doesn't necessarily improve the underlying economics of the health plan.
For 2027, nearly half of large employers surveyed by Mercer expect to make medical-plan changes that increase employees' out-of-pocket costs.[6]
That makes affordability an increasingly important part of benefits strategy.
Before shifting additional costs to employees, employers should investigate whether opportunities exist within pharmacy contracting, utilization management, provider strategy or the funding structure itself.
Frequently Asked Questions
Should employers cover GLP-1 weight-loss drugs in 2027?
There is no universal answer. Employers should evaluate workforce needs, utilization, pharmacy costs, clinical criteria, PBM arrangements and the financial impact of coverage. Some employers are maintaining coverage with tighter utilization controls, while others are eliminating obesity-related coverage.
Are fewer employers covering GLP-1s for weight loss?
Yes. In Business Group on Health's 2027 strategy survey, GLP-1 obesity coverage among surveyed employers declined from 72% in 2025 to 60% in 2026.[1]
How much of employer healthcare spending goes to prescription drugs?
Among employers surveyed by Business Group on Health, pharmacy represented approximately 25% of total healthcare spending in 2026.[1]
Can an employer require prior authorization for GLP-1 coverage?
Employer health plans commonly use prior authorization and other utilization-management approaches. The specific design should be coordinated with the plan's carrier or PBM and appropriate benefits, clinical and legal advisors.
Do GLP-1 medications have benefits beyond weight loss?
Some do, depending on the specific medication and patient. For example, the FDA has approved Wegovy for reducing the risk of cardiovascular death, heart attack and stroke in certain adults with cardiovascular disease and obesity or overweight.[2]
Should an employer review its PBM because of GLP-1 costs?
Potentially. Rapidly rising GLP-1 utilization may be one reason to examine the broader pharmacy arrangement, including formulary design, rebates, contract structure, utilization-management programs and PBM compensation.
The Bigger Question for Employers
The GLP-1 debate illustrates a much larger change occurring in employee benefits.
Employers are being asked to fund increasingly sophisticated—and increasingly expensive—healthcare.
At the same time, employees expect benefits to remain affordable and competitive.
There will rarely be a simple answer.
The employers best positioned for this environment will be those that understand their data, scrutinize their vendors, evaluate alternative funding strategies and make deliberate decisions about where healthcare dollars create the most value.
Proper Benefits Brokerage helps employers evaluate their health plan, pharmacy strategy and funding structure to identify opportunities for greater transparency and long-term cost control.
If your organization has 50+ employees and is evaluating its 2027 benefits strategy, we can help you determine which options deserve a closer look.
Talk with Proper Benefits Brokerage about your 2027 benefits strategy.